A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
Articolo
Data di Pubblicazione:
2012
Citazione:
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer / Kindler, Hl; Richards, Da; Garbo, Le; Garon, Eb; Stephenson JJ, Jr; Rocha Lima, Cm; Safran, H; Chan, D; Kocs, Dm; Galimi, Francesco; Mcgreivy, J; Bray, Sl; Hei, Y; Feigal, Eg; Loh, E; Fuchs, Cs. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:11(2012), pp. 2834-2842. [10.1093/annonc/mds142]
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Kindler, Hl; Richards, Da; Garbo, Le; Garon, Eb; Stephenson JJ, Jr; Rocha Lima, Cm; Safran, H; Chan, D; Kocs, Dm; Galimi, Francesco; Mcgreivy, J; Bray, Sl; Hei, Y; Feigal, Eg; Loh, E; Fuchs, Cs
Link alla scheda completa:
Pubblicato in: